YDES Could Be 2026's Biotech Breakthrough

The Biotech Story Wall Street Could Be All Over in 2026. ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  

You are receiving this email because you are subscribed to Morning Watchlist from Behind the Markets. If you no longer wish to receive these partner emails, please unsubscribe here. This message is from Small Caps Daily. YD Bio Ltd. (NASDAQ: YDES) is Pioneering the Next Era of Cancer Diagnostics and Advanced Eye Care While Driving Commercial Revenue RIGHT NOW. YD Bio Ltd. (NASDAQ: YDES) is setting itself apart by turning breakthrough science into commercial solutions. The company's OkaiDx™ liquid biopsy platform now enables early detection of pancreatic, colorectal, and breast cancers across most of the U.S., combining non-invasive testing with at-home blood collection and telehealth support. At the same time, YDES's FDA-cleared Exovisse® contact lenses and artificial tears are generating near-term revenue while laying the foundation for next-generation regenerative therapies. With 20-year strategic agreements with EG Biomed and 3D Global Biotech, YDES has secured exclusive access to advanced molecular diagnostics and stem cell-derived exosome therapies, positioning itself at the forefront of two of healthcare's fastest-growing markets. YDES isn't waiting for approvals or hypothetical breakthroughs — it's already in the market, scaling its diagnostics and eye care solutions while building a robust pipeline for the future. From U.S. expansion with a new California operations hub to growing clinical validation of its early cancer detection platform, YDES is combining execution, innovation, and strategic partnerships for long-term impact. In 2026, YDES could redefine what it means to be a biotech leader. By turning liquid biopsy technology into a nationwide cancer detection platform and pairing it with regenerative ocular therapies, YD Bio is tackling two of healthcare's fastest-growing markets simultaneously. Explore how YDES is positioned at the center of two of healthcare's fastest-growing markets. We are issuing this disclosure in compliance with Section 17(b) of the Securities Act, which requires us to disclose any compensation received or expected to be received in cash or in kind in connection with the purchase or sale of any security. We would like to inform you that we have received or expect to receive compensation in connection with the purchase or sale of the securities of YD Bio Ltd. (NASDAQ: YDES). The compensation consists of up to $6,500 and was received/will be received from Interactive Offers. This communication should not be considered as an endorsement of the securities of adviser YD Bio Ltd. (NASDAQ: YDES) and we are not responsible for any errors or omissions in any information provided about the securities of YD Bio Ltd. (NASDAQ: YDES) or Interactive Offers. We encourage you to conduct your own due diligence and research before making any investment decisions. You should also consult with a financial advisor before making any investment decisions. This disclosure is made as of 1/7/2026. Our mailing address is: Behind the Markets, LLC 4260 NW 1st Avenue, Suite 55 Boca Raton, FL 33431 Copyright © 2024 Behind the Markets, LLC, All rights reserved. You're receiving this email as part of your subscription to Behind the Markets. For more information about our privacy practices, please review our Privacy Policy or our Legal Notices. Behind the Markets You are receiving this email because you are subscribed to Morning Watchlist from Behind the Markets. If you no longer wish to receive these partner emails, please unsubscribe here.